NCT07052903 - TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | Biotech Hunter

Enrollment

1,250

Participants

Timeline

Start Date

July 2, 2025

Primary Completion Date

May 28, 2030

Study Completion Date

November 30, 2032

Conditions

Transthyretin Amyloidosis With Cardiomyopathy

Interventions

DRUG

Nucresiran

Nucresiran 300 mg administered SC q6M

DRUG

Sterile Normal Saline (0.9% NaCl)

Sterile Normal Saline (0.9% NaCl) administered SC once q6M

Trial Locations (17)

10065

RECRUITING

Clinical Trial Site, New York

19104

RECRUITING

Clinical Trial Site, Philadelphia

20010

RECRUITING

Clinical Trial Site, Washington D.C.

30041

RECRUITING

Clinical Trial Site, Cumming

30501

RECRUITING

Clinical Trial Site, Gainesville

33511

RECRUITING

Clinical Trial Site, Brandon

48202

RECRUITING

Clinical Trial Site, Detroit

63110

RECRUITING

Clinical Trial Site, St Louis

02118

RECRUITING

Clinical Trial Site, Boston

Unknown

RECRUITING

Clinical Trial Site, Fukuoka

RECRUITING

Clinical Trial Site, Christchurch

RECRUITING

Clinical Trial Site, Basel

RECRUITING

Clinical Trial Site, Geneva

RECRUITING

Clinical Trial Site, Lucerne

RECRUITING

Clinical Trial Site, Cardiff

RECRUITING

Clinical Trial Site, Edgbaston

RECRUITING

Clinical Trial Site, Manchester